Key Points
- Insider sale: Jorge Andres Cedron sold 3,743 shares on April 16 at an average price of $12.82 to cover tax withholding, reducing his stake by 5.97% and leaving him with 59,006 shares valued at about $756,457.
- Company financials: Orthofix (NASDAQ:OFIX) has a market cap of roughly $508M, reported Q4 revenue of $219.9M and EPS of ($0.06), with a negative net margin (~-11.2%) and analysts forecasting about -$1.57 EPS for the year.
- Market view and ownership: Analysts are mixed (average rating: "Hold" with a $17.25 target) and institutional investors control about 89.8% of the stock.
Orthofix Medical Inc. (NASDAQ:OFIX - Get Free Report) insider Jorge Andres Cedron sold 3,743 shares of the company's stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $12.82, for a total value of $47,985.26. Following the completion of the transaction, the insider directly owned 59,006 shares in the company, valued at $756,456.92. This trade represents a 5.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Orthofix Medical Stock Performance
OFIX stock opened at $12.65 on Tuesday. The stock has a market capitalization of $507.77 million, a PE ratio of -5.41 and a beta of 0.82. Orthofix Medical Inc. has a 12-month low of $10.24 and a 12-month high of $16.99. The company has a current ratio of 2.45, a quick ratio of 1.43 and a debt-to-equity ratio of 0.39. The stock's 50 day simple moving average is $12.50 and its 200 day simple moving average is $14.08.
Orthofix Medical (NASDAQ:OFIX - Get Free Report) last released its quarterly earnings data on Saturday, February 14th. The medical device company reported ($0.06) earnings per share (EPS) for the quarter. The business had revenue of $219.91 million during the quarter. Orthofix Medical had a negative net margin of 11.21% and a negative return on equity of 20.38%. As a group, research analysts forecast that Orthofix Medical Inc. will post -1.57 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
OFIX has been the subject of a number of recent analyst reports. Wall Street Zen raised Orthofix Medical from a "hold" rating to a "buy" rating in a research report on Saturday, March 7th. Weiss Ratings reissued a "sell (d-)" rating on shares of Orthofix Medical in a research report on Thursday, January 22nd. TD Cowen began coverage on shares of Orthofix Medical in a research report on Tuesday, January 27th. They issued a "hold" rating and a $14.00 target price for the company. Canaccord Genuity Group cut their target price on shares of Orthofix Medical from $24.00 to $20.00 and set a "buy" rating for the company in a research report on Thursday, February 26th. Finally, Stifel Nicolaus cut their target price on shares of Orthofix Medical from $22.00 to $18.00 and set a "buy" rating for the company in a research report on Monday, March 9th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $17.25.
Check Out Our Latest Stock Analysis on OFIX
Hedge Funds Weigh In On Orthofix Medical
Hedge funds have recently modified their holdings of the company. CWM LLC boosted its position in shares of Orthofix Medical by 99.0% in the third quarter. CWM LLC now owns 1,920 shares of the medical device company's stock worth $28,000 after purchasing an additional 955 shares during the period. State of Alaska Department of Revenue bought a new position in shares of Orthofix Medical in the third quarter worth approximately $30,000. Kestra Advisory Services LLC bought a new position in shares of Orthofix Medical in the fourth quarter worth approximately $56,000. Mackenzie Financial Corp bought a new position in shares of Orthofix Medical in the third quarter worth approximately $148,000. Finally, Strs Ohio bought a new position in shares of Orthofix Medical in the first quarter worth approximately $150,000. 89.76% of the stock is currently owned by institutional investors.
About Orthofix Medical
(
Get Free Report)
Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company's core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.
Orthofix's product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
